Effect of Cytokine Gene Polymorphisms on Eltrombopag Reactivity in Japanese Patients with Immune Thrombocytopenia

References

• Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med. 2002;346(13):995–1008. doi:10.1056/NEJMra010501
   PubMed Web of Science ®Google Scholar
• Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386–2393. doi:10.1182/blood-2008-07-162503
   PubMed Web of Science ®Google Scholar
• Semple JW, Milev Y, Cosgrave D, et al. Differences in serum cytokines levels in acute and chronic autoimmune thrombocytopenic purpura: relationhip to platelet phenotype and antiplatelet T-cell reactivity. Blood. 1996;87(10):4245–4254. doi:10.1182/blood.V87.10.4245.bloodjournal87104245
   PubMed Web of Science ®Google Scholar
• Kuwana M, Kaburaki J, Ikeda Y. Autoreactive T cells to platelet GPIIb-IIIa in immune thrombocytopenic purpura: role in production of antiplatelet autoantibody. J Clin Invest. 1998;102(7):1393–1402. doi:10.1172/JCI4238
   PubMed Web of Science ®Google Scholar
• Nomura S, Matsuzaki T, Ozaki Y, et al. Clincal significance of HLA-DRB1*0410 in Japanese patients with idiopathic thrombocytopenic purpura. Blood. 1998;91(10):3616–3622. doi:10.1182/blood.V91.10.3616
   PubMed Web of Science ®Google Scholar
• Kuwana M, Kaburaki J, Kitasato H, et al. Immunodominant epitopes on glycoprotein IIb-IIIa recognized by autoreactive T cells in patients with immune thrombocytopenic purpura. Blood. 2001;98(1):130–139. doi:10.1182/blood.V98.1.130
   PubMed Web of Science ®Google Scholar
• Zufferey A, Kapur R, Semple JW. Pathogenesis and therapeutic mechanisms in immune thrombocytopenia (ITP). J Clin Med. 2017;6(2):16. doi:10.3390/jcm6020016
   PubMed Web of Science ®Google Scholar
• Li J, Sullivan JA, Ni H. Pathophysiology of immune thrombocytopenia. Curr Opin Hematol. 2018;25(5):373–381. doi:10.1097/MOH.0000000000000447
   PubMed Web of Science ®Google Scholar
• Marini I, Backhoul T. Pathophysiol of autoimmune thrombocytopenia: current insight with a focus on thrombopoiesis. Hamostaseologie. 2019;39(3):227–237. doi:10.1055/s-0039-1678732
   Web of Science ®Google Scholar
• Cooper N. State of the art – how I manage immune thrombocytopenia. Br J Haematol. 2017;177(1):39–54. doi:10.1111/bjh.14515
   PubMed Web of Science ®Google Scholar
• Miltiadous O, Hou M, Bussel JB. Identifying and treating refractory ITP: difficulty in diagnosis and role of combination treatment. Blood. 2020;135(7):472–490. doi:10.1182/blood.2019003599
   PubMed Web of Science ®Google Scholar
• Nomura S. Advances in diagnosis and treatment for immune thrombocytopenia. Clin Med Insight Blood Disord. 2016;9:15–22.
   Google Scholar
• Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007;357(22):2237–2247. doi:10.1056/NEJMoa073275
   PubMed Web of Science ®Google Scholar
• Bussel JB, Kuter DJ, Pullarkat V, et al. Safty and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood. 2009;113(10):2161–2171. doi:10.1182/blood-2008-04-150078
   PubMed Web of Science ®Google Scholar
• Kuter DJ, Rummel M, Roccia R, et al. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med. 2010;363(20):1889–1899. doi:10.1056/NEJMoa1002625
   PubMed Web of Science ®Google Scholar
• Cheng G, Saleh MN, Marcher C, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomized, Phase 3 study. Lancet. 2011;377(9763):393–402. doi:10.1016/S0140-6736(10)60959-2
   PubMed Web of Science ®Google Scholar
• Taylor A, Westwood JP, Laskou F, McGuckin S, Scully M. Thrombopoietin receptor agonist therapy in thrombocytopenia: ITP and beyond. Br J Haematol. 2017;177(3):475–480. doi:10.1111/bjh.14564
   Web of Science ®Google Scholar
• Wong RSM, Saleh MN, Khelif A, et al. Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study. Blood. 2017;130(23):2527–2536. doi:10.1182/blood-2017-04-748707
   PubMed Web of Science ®Google Scholar
• Ghanima W, Cooper N, Rodeghiero F, Godeau B, Bussel JB. Thrombopoietin receptor agonists: tenyears later. Haematologica. 2019;104(6):1112–1123. doi:10.3324/haematol.2018.212845
   PubMed Web of Science ®Google Scholar
• Bax M, van Heemst J, Huizinga TWJ, Toes REM. Genetics of rheumatoid arthritis: what have we learned? Immunogenetics. 2011;63(8):459–466. doi:10.1007/s00251-011-0528-6
   PubMed Web of Science ®Google Scholar
• Bettinotti MP, Hartung K, Deicher H, et al. Polymorphism of the tumor necrosis factor beta gene in systemic lupus erythematosus; TNFB-MHC haplotypes. Immunogenetics. 1993;37(6):449–454. doi:10.1007/BF00222469
   Web of Science ®Google Scholar
• Vandevyver C, Raus P, Stinisen P, et al. Polymorphism of the tumor necrosis factor beta gene in multiple sclerosis and rheumatoid arthritis. Eur J Immunogenet. 1994;21(5):377–382. doi:10.1111/j.1744-313X.1994.tb00208.x
   Google Scholar
• Bidwell J, Keen L, Gallagher G, et al. Cytokine gene polymorphism in human disease: online databeses. Gene Immunol. 1999;1(1):3–19. doi:10.1038/sj.gene.6363645
   PubMed Web of Science ®Google Scholar
• Atabay B, Oren H, Irken G, et al. Role of transforming growth factor-beta 1 gene polymorphisms in childhood idiopathic thrombocytopenic purpura. J Pediatr Hematol Oncol. 2003;25(11):885–889. doi:10.1097/00043426-200311000-00012
   Web of Science ®Google Scholar
• Satoh T, Pandey JP, Okazaki Y, et al. Single nucleotide polymorphisms of the inflammatory cytokine genes in adults with chronic immune thrombocytopenic purpura. Br J Haematol. 2004;124(6):796–801. doi:10.1111/j.1365-2141.2004.04843.x
   PubMed Web of Science ®Google Scholar
• Wu KH, Peng CT, Li TC, et al. Interleukin 4, interleukin 6 and interleukin 10 polymorphisms in children with acute and chronic immune thrombocytopenic purpura. Br J Haematol. 2005;128(6):849–852. doi:10.1111/j.1365-2141.2005.05385.x
   PubMed Web of Science ®Google Scholar
• Emmerich F, Bal G, Barakat A, et al. High-level serum B-cell activating factor and promorter polymorphisms in patients with idiopathic thrombocytopenic purpura. Br J Haematol. 2007;136(2):309–314. doi:10.1111/j.1365-2141.2006.06431.x
   Web of Science ®Google Scholar
• Ma D, Zhu X, Zhao P, et al. Profile of Th17 cytokines (IL-17, TGF-β, IL-6) and Th1 cytokine (IFN-γ) in patients with immune thrombocytopenic purpura. Ann Hematol. 2008;87(11):899–904. doi:10.1007/s00277-008-0535-3
   PubMed Web of Science ®Google Scholar
• Okulu E, Ileri T, Kosan Culha V, et al. The role of tumor necrosis factor-alpha −308 G/A and transforming growth factor-beta 1-915 G/C polymorphisms in childhood idiopathic thrombocytopenic purpura. Turk J Haematol. 2011;28(3):170–175. doi:10.5152/tjh.2011.50
   Web of Science ®Google Scholar
• Pehlivan M, Okan V, Sever T, et al. Investigation of TNF-alpha, TGF-beta 1, IL-10, IFN-gamma, MBL, GPIA, and IL1A gene polymorphisms in patients with idiopathic thrombocytopenic purpura. Platelets. 2011;22(8):588–595. doi:10.3109/09537104.2011.577255
   PubMed Web of Science ®Google Scholar
• Saitoh T, Kasamatsu T, Inoue M, et al. Interkeukin-10 gene polymorphism reflects the severity of chronic immune thrombocytopenia in Japanese patients. Int J Lab Hematol. 2011;33(5):526–532. doi:10.1111/j.1751-553X.2011.01320.x
   Web of Science ®Google Scholar
• Tesse R, Del Vecchio GC, Demattia D, et al. Association of interleukin-(IL)10 haplotypes and serum IL-10 levels in the progression of childhood immune thrombocytopenic purpura. Gene. 2012;505(1):53–56. doi:10.1016/j.gene.2012.05.050
   PubMed Web of Science ®Google Scholar
• Zhao H, Zhang Y, Xiao G, et al. Interleukin-18 gene promoter—607 A/C polymorphism and the risk of immune thrombocytopenia. Autoimmunity. 2014;47(7):478–481. doi:10.3109/08916934.2014.921812
   PubMed Web of Science ®Google Scholar
• Pavkovic M, Angelovic R, Popova-Simjanovska M, et al. Single nucleotide polymorphisms of the inflammatory xcytokine genes: interleukin-1B, tumor necrosis factor-A and tumor necrosis factor-B in adult patients with immune thrombocytopenia. Pril. 2015;36(1):109–115. doi:10.1515/prilozi-2015-0035
   Google Scholar
• Ghannam DEI, Fawzy IM, Azmy E, Hakim H, Eid I. Relation of interleukin-10 promorter polymorphisms to ault chronic immune thrombocytopenic purpura in a cohort of Egyptian population. Immunol Invest. 2015;44(7):616–626. doi:10.3109/08820139.2015.1064948
   Web of Science ®Google Scholar
• Yadav DK, Tripathi AK, Kumar A, et al. Association of TNF-α −308 G>A and TNF-β +252 A.G genes polymorphisms with primary immune thrombocytopenia: a North Indian study. Blood Coagul Fibrinolysis. 2016;27(7):791–796. doi:10.1097/MBC.0000000000000492
   Web of Science ®Google Scholar
• Morgan DS, Afifi RA, EI-Hoseiny SM, Amin DG, Ibrahim SYG. The potential association of tumor necrosis factor-β (252 G/A) cytokine gene polymorphism with immune thrombocytopenic purpura among Egyptian children. Hematology. 2018;23(5):299–303. doi:10.1080/10245332.2017.1386429
   Web of Science ®Google Scholar
• Ou Y, Yang Y, Xiang X, Wu Y. Relationship between the IL-10 (−1082 A/G) polymorphism and the risk of immune/idiopathic thrombocytopenic purpura: a meta-analysis. Cytokine. 2020;125:154820. doi:10.1016/j.cyto.2019.154820
   PubMed Web of Science ®Google Scholar
• AI-Samkari H, Kuter DJ. Immune thrombocytopenia in adults: modern approaches to diagnosis and treatment. Semin Thromb Hemost. 2020;46(3):275–288. doi:10.1055/s-0039-1700512
   Web of Science ®Google Scholar
• Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115(2):168–186. doi:10.1182/blood-2009-06-225565
   PubMed Web of Science ®Google Scholar
• Neunert C, Noroozi N, Norman G, et al. Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review. J Thromb Haemost. 2015;13(3):457–464. doi:10.1111/jth.12813
   PubMed Web of Science ®Google Scholar
• Tsujimoto S, Ozaki Y, Ito T, Nomura S. Usefukness of cytokine gene polymorphisms for the therapeutic choice in Japanese patients with rheumatoid arthritis. Int J Gene Med. 2021;14:131–139. doi:10.2147/IJGM.S287505
   Web of Science ®Google Scholar
• Letterio JJ, Roberts AB. Regulation of immune responses by TGF-β. Annu Rev Immunol. 1998;16:137–161. doi:10.1146/annurev.immunol.16.1.137
   PubMed Web of Science ®Google Scholar
• Gualtierotti R, Biggioggero M, Penatti AE, Meroni PL. Updating on the pathogenesis of systemic lupus erythematosus. Autoimmun Rev. 2010;10(1):3–7. doi:10.1016/j.autrev.2010.09.007
   PubMed Web of Science ®Google Scholar
• Su DL, Lu ZM, Shen MN, Li X, Sun LY. Roles of pro- and anti-inflammatory cytokines in the pathogenesis of SLE. J Biomed Biotechnol. 2012;2012:347141. doi:10.1155/2012/347141
   PubMed Web of Science ®Google Scholar
• Shull MM, Ormsby I, Kier AB, et al. Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease. Nature. 1992;359(6397):693–699. doi:10.1038/359693a0
   PubMed Web of Science ®Google Scholar
• Mosser DM, Zhang X. Interleukin-10: new perspectives on an old cytokine. Immunol Rev. 2008;226:205–218. doi:10.1111/j.1600-065X.2008.00706.x
   PubMed Web of Science ®Google Scholar
• Tian G, Li JL, Wang DG, Zhou D. Targeting IL-10 in auto-immune diseases. Cell Biochem Biophys. 2014;70(1):37–49. doi:10.1007/s12013-014-9903-x
   PubMed Web of Science ®Google Scholar
• Ma L, Liang Y, Fang M, et al. The cytokines (IFN-gamma, IL-2, IL-4, IL-10, IL-17) and Treg cytokine (TGF-beta1) kevels in adult with immune thrombocytopenia. Pharmazie. 2014;69(9):694–697.
   Web of Science ®Google Scholar
• Goelz N, Bosch AMS, Rand ML, et al. Increased levels of IL-10 and IL-1Ra counterbalance the proinflammatory cytokine pattern in acute pediatric immune thrombocytopenia. Cytokine. 2020;130:155078. doi:10.1016/j.cyto.2020.155078
   Web of Science ®Google Scholar
• Ma L, Simpson E, Li J, et al. CD8+ T cells are predominantly protective and required for effective steroid therapy in murine models of immune thrombocytopenia. Blood. 2015;126(2):247–256. doi:10.1182/blood-2015-03-635417
   PubMed Web of Science ®Google Scholar
• Gonzalez-Porras JR, Bastida JM. Eltrombopag in immune thrombocytopenia: efficacy review and update on drug safety. The Adv Drug Saf. 2018;9(6):263–285. doi:10.1177/2042098618769587
   PubMed Web of Science ®Google Scholar
• Fujita S, Nakanishi T, Yoshimura H, et al. TGFβ1 and sCTLA-4 levels are increased in eltrombopag-exposed patients with ITP. Thromb Res. 2012;130(3):415–419. doi:10.1016/j.thromres.2012.06.002
   PubMed Web of Science ®Google Scholar
• Bao W, Bussel JB, Heck S, et al. Improved regulatory T-cellactivity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents. Blood. 2010;116(22):4639–4645. doi:10.1182/blood-2010-04-281717
   PubMed Web of Science ®Google Scholar